История выручки, прибыли и денежных потоков из официальной финансовой отчётности.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Интерактивные графики и полная отчётность → Модель оценки (DCF) →
| Отчёт о прибылях и убытках | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общая выручка | $831M | $761M | $675M | $482M | $402M | $366M | $354M | $306M | $251M | $159M | $81M | $50M | $27M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| Валовая прибыль | $817M | $748M | $664M | $476M | $396M | $361M | $348M | $301M | $246M | $156M | $79M | $49M | $26M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| Валовая маржа % | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% | 97.3% | 96.7% | 98.6% | 97.2% | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Операционная прибыль (EBIT) | $6M | $45M | $137M | $107M | $113M | $124M | $128M | $112M | $89M | $53M | $10M | ($3M) | ($28M) | ($41M) | ($36M) | ($32M) | ($27M) | ($20M) | ($20M) | ($12M) | ($26M) |
| Операционная маржа % | 0.8% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% | -6.9% | -104.0% | -400.7% | -1096.8% | — | — | -69827.6% | -9420.6% | -2540.5% | -8701.4% |
| Чистая прибыль | $55M | $100M | $140M | $106M | $101M | $113M | $106M | $94M | $75M | $129M | $8M | ($6M) | ($31M) | ($46M) | ($38M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($25M) |
| Чистая маржа % | 6.6% | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% | -12.7% | -118.2% | -444.2% | -1150.5% | — | — | -69537.9% | -9598.6% | -2401.0% | -8460.2% |
| EBITDA | $23M | $68M | $163M | $126M | $116M | $128M | $130M | $114M | $90M | $53M | $10M | ($3M) | ($27M) | ($41M) | ($36M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($26M) |
| Прибыль на акцию (EPS) | $0.42 | $0.83 | $1.23 | $0.95 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | $-0.06 | $-0.31 | $-0.46 | $-0.41 | $-0.39 | $-0.38 | $-0.38 | $-0.43 | $-0.34 | $-1.09 |
| Акции в обращении (M) | 118M | 120M | 113M | 112M | 116M | 126M | 124M | 123M | 127M | 125M | 116M | 107M | 101M | 100M | 93M | 83M | 68M | 52M | 47M | 34M | 23M |
Источник: публичная отчётность компании (SEC). Сверяйте с SEC EDGAR, прежде чем полагаться на любую цифру.
Балансы, денежные потоки, квартальные данные и финансовые коэффициенты — в интерактивном просмотрщике CORT. /companies/us/CORT
Информация на сайте предназначена исключительно для образовательных и информационных целей и не является инвестиционной рекомендацией. Целевые цены и рекомендации не публикуются.
About TickerBase · Data methodology & sources · Privacy · Terms